Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production

2020; American Society for Microbiology; Volume: 64; Issue: 10 Linguagem: Inglês

10.1128/aac.00825-20

1098-6596

Natália Fintelman-Rodrigues, Carolina Q. Sacramento, Carlyle Ribeiro Lima, Franklin Souza‐Silva, André C. Ferreira, Mayara Mattos, Caroline S. de Freitas, Vinícius Cardoso Soares, Suelen da Silva Gomes Dias, Jairo R. Temerozo, Milene Dias Miranda, Aline da Rocha Matos, Fernando A. Bozza, Nicolas Carels, Carlos Roberto Alves, Marilda Mendonça Siqueira, Patrı́cia T. Bozza, Thiago Moreno L. Souza,

Mosquito-borne diseases and control

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor.